alexa Abstract | Novel Agents and Future Prospects in the Treatment of Pancreatic Adenocarcinoma

JOP. Journal of the Pancreas
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Abstract

Pancreatic adenocarcinoma is one of the most aggressive malignancies and the fourth leading cause of cancer-relatedmortality in the United States. The majority of patients are diagnosed at advanced stage with inoperable locally advancedtumors or metastatic disease, and palliative chemotherapy remains the best therapeutic option for these patients. Despiteintensive clinical and pre-clinical research over the last few years, the combination of the anti-metabolite drug gemcitabinewith the targeted agent erlotinib, is considered standard of care in the treatment of these patients, with only minimal ormodest efficacy. Therefore, novel therapeutic approaches are currently under clinical investigation in an attempt to producemore definite results for this fatal disease. In this paper we summarize five most interesting research abstracts as presentedat the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. In two studies, nimotuzumab, a monoclonalantibody against epidermal growth factor receptor (EGFR) (Abstract #4009) and bavituximab, a monoclonal antibodyagainst phosphatidylserine (Abstract #4054) are tested in combination with gemcitabine in patients with advancedpancreatic cancer. Abstract #4012 is a study of gemcitabine with vismodegib, a novel hedgehog pathway inhibitor, whereasin Abstract #4035, toxicity and efficacy results of sunitinib in combination with gemcitabine in patients with pancreaticadenocarcinoma are presented. Lastly, safety results of pimasertib, a novel mitogen-activated protein kinase kinase (MEK)inhibitor, combined with the standard gemcitabine are presented in Abstract #4041.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Muhammad Wasif Saif Konstantinos N Syrigos Evangelos G Sarris

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords